Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug

Dr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agreement includes developing Lenacapavir for both treatment and potential prevention of HIV. This collaboration aims to make this advanced treatment accessible in regions with high HIV burdens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HZbqXu5
via IFTTT